mesothelioma study

Clinical Trial Tests Drug Combination in Mesothelioma

UPDATE: Aduro Biotech announced on December 12 that they have decided to discontinue its CRS-207 clinical trial and wind down each of its trials in mesothelioma. This decision was made based on preliminary results from the trials, as well as a business and commercial assessment.
On November 8, 2017, the Meso Foundation hosted a Meet the Mesothelioma […]


Anetumab Ravtansine Fails to Show Improvement of Progression-Free Survival in Mesothelioma

In a statement released on Sunday, Bayer announced that Anetumab ravtansine, its antibody-drug conjugate (ADC) tested in mesothelioma, has missed its primary endpoint failing to improve progression-free survival in mesothelioma patients.
“Malignant pleural mesothelioma is a very difficult-to-treat tumor, and we had hoped for a better outcome for patients,” said Robert LaCaze, Executive Vice President and […]


Genentech Halts Avastin Approval Filing for Mesothelioma

In 2015, data was presented at the American Society of Clinical Oncology (ASCO) Annual Meeting from a Phase III French study that demonstrated improved survival rates for patients who received bevacizumab (Avastin® Genentech, Inc.) in addition to the standard chemotherapy regimen of pemetrexed/cisplatin.
The outcome of the study prompted the independent French cooperative group and Genentech […]


Updates in Mesothelioma Research from ASCO 2017

The American Society of Clinical Oncology (ASCO) held its Annual Meeting on June 2-6, 2017 in Chicago. The Meso Foundation’s CEO, Melinda Kotzian, had the opportunity to attend the conference and hear the latest news reported in mesothelioma research.
Hedy Lee Kindler, MD, of the University of Chicago, presented a poster on the results from a […]


Results Show Encouraging Survival Data: Nintedanib for Mesothelioma

On June 5, Anna Nowak, MD, PhD, of the University of Western Australia and member of the Meso Foundation’s Science Advisory Board, presented phase II results from LUME-Meso, a mesothelioma clinical trial sponsored by Boehringer Ingelheim, at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.
LUME-Meso is a randomized, double-blind, placebo-controlled trial evaluating […]